Vertex Moves Toward CF Specialty Model, Will End Investment In Hepatitis C
Executive Summary
While it will seek to out-license mid-stage HCV antiviral VX-135, Vertex is garnering promising data with a pair of CFTR correctors that may broaden the patient base for its cystic fibrosis portfolio.